<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01259297</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100G2301</org_study_id>
    <secondary_id>2009-010170-38</secondary_id>
    <nct_id>NCT01259297</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People</brief_title>
  <acronym>APOLLO</acronym>
  <official_title>A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study was planned to provide new information regarding the role of aliskiren (with or
      without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly
      individuals (â‰¥ 65 years) with systolic blood pressure (SBP) 130 to 159 mmHg, in preventing
      major cardiovascular (CV) events and on global measures of physical, executive and cognitive
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was 2x2 factorial design study with 2 strata. As per protocol, the first co- Primary
      analysis as well as secondary analysis were aliskiren based regimen vs non-aliskiren based
      regimen. All aliskiren based arm were combined into the aliskiren based regimen and all
      non-aliskiren based arms were combined into non-aliskiren based regimen.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early in agreement with Health Authorities for feasibility reasons
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen</measure>
    <time_frame>End of study (209 days (median))</time_frame>
    <description>The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Composite Cardiovascular Endpoints in Aliskiren+Amlodipine/HCTZ Group Versus All Placebo Group</measure>
    <time_frame>End of study (209 days (median))</time_frame>
    <description>The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Study in Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part I)</measure>
    <time_frame>Baseline, End of study (209 days [median])</time_frame>
    <description>Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part I of SAGE included 4 dimensions:
Community Cognition (maximum of scores of questions 1 to 6);
Instrumental Activities of daily Living (IADL) (maximum of scores of questions 7 to 10);
Mobility (maximum of scores of questions 11 and 12);.
Basic Activities of daily Living (ADL) (maximum of scores of questions 13 to 15) Each dimension's total score ranged from 0 to 3. 0=best, 3=worst A negative change in value from baseline means improvement in the ability to perform everyday activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part II)</measure>
    <time_frame>End of study (209 days [median])</time_frame>
    <description>Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE was comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in the last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)).
Part II of SAGE included 2 dimensions:
&quot;Normal&quot; if the scores of all SAGE questions is 0 (i.e., No difficulty)
&quot;Mobility Only&quot; if scores of both SAGE questions 11 and 12 are 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Renal Dysfunction in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen</measure>
    <time_frame>End of study (209 days (median))</time_frame>
    <description>The renal dysfunction (composite endpoint) was defined as the first occurrence of either of the following:
End-stage renal disease [ESRD] requiring dialysis or transplantation
Doubling of serum creatinine and reaching an eGFR &lt; 45 ml/min/1.73 m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen</measure>
    <time_frame>End of study (209 days (median))</time_frame>
    <description>The total mortality endpoint was defined as time to death from any cause. Total mortality analysis used the date of last follow-up including the washout period as the censoring date.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</measure>
    <time_frame>Baseline (BL), 6 week, 6 month and 12 month</time_frame>
    <description>Mean sitting systolic blood pressure (msSBP) is the average of 2 sitting SBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>Baseline (BL), 6 week, 6 month and 12 month</time_frame>
    <description>Mean sitting diastolic blood pressure (msDBP) is the average of 2 sitting DBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">2336</enrollment>
  <condition>Cardiovascular Events</condition>
  <arm_group>
    <arm_group_label>Aliskiren + Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.
In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren + Hydrochlorothiazide (HCTZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.
In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren + Placebo for Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for Amlodipine 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren + Placebo for HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for HCTZ 25 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine + Placebo for Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ + Placebo for Aliskiren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Aliskiren + Placebo for Amlodipine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Aliskiren + Placebo for HCTZ</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 150/300 mg once daily</description>
    <arm_group_label>Aliskiren + Amlodipine</arm_group_label>
    <arm_group_label>Aliskiren + Hydrochlorothiazide (HCTZ)</arm_group_label>
    <arm_group_label>Aliskiren + Placebo for Amlodipine</arm_group_label>
    <arm_group_label>Aliskiren + Placebo for HCTZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 5 mg</description>
    <arm_group_label>Aliskiren + Amlodipine</arm_group_label>
    <arm_group_label>Amlodipine + Placebo for Aliskiren</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide (HCTZ)</intervention_name>
    <description>HCTZ 12.5/25 mg</description>
    <arm_group_label>Aliskiren + Hydrochlorothiazide (HCTZ)</arm_group_label>
    <arm_group_label>HCTZ + Placebo for Aliskiren</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Aliskiren</intervention_name>
    <description>Placebo for Aliskiren 300 mg</description>
    <arm_group_label>Amlodipine + Placebo for Aliskiren</arm_group_label>
    <arm_group_label>HCTZ + Placebo for Aliskiren</arm_group_label>
    <arm_group_label>Placebo for Aliskiren + Placebo for Amlodipine</arm_group_label>
    <arm_group_label>Placebo for Aliskiren + Placebo for HCTZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Amlodipine</intervention_name>
    <description>Placebo for Amlodipine</description>
    <arm_group_label>Aliskiren + Placebo for Amlodipine</arm_group_label>
    <arm_group_label>Placebo for Aliskiren + Placebo for Amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Hydrochlorothiazide (HCTZ)</intervention_name>
    <description>Placebo for HCTZ 12.5/25 mg</description>
    <arm_group_label>Aliskiren + Placebo for HCTZ</arm_group_label>
    <arm_group_label>Placebo for Aliskiren + Placebo for HCTZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Systolic blood pressure 130 - 159 mmHg with any one of the following (1, 2 or 3):

          1. Men and women aged â‰¥ 65 years if they have at least one of the following: (secondary
             prevention) Coronary heart disease

               -  Previous myocardial infarction or

               -  Stable angina or unstable angina with documented multi-vessel coronary artery
                  disease, &gt; 50% stenosis in at least 2 major coronary arteries on coronary
                  angiography, or positive stress test (ECG or nuclear perfusion scintogram), or

               -  Multi-vessel PCI, or

               -  Multi-vessel CABG surgery &gt; 4 years prior to informed consent, or with recurrent
                  angina or ischemia following surgery Stroke/TIA Previous documented stroke or
                  documented TIA &lt; 1 year before informed consent Peripheral artery disease

               -  Previous limb bypass surgery or percutaneous transluminal angioplasty, or

               -  Previous limb or foot amputation, or

               -  History of intermittent claudication, with an ankle:arm BP ratio â‰¤ 0.80 on at
                  least one side, or significant peripheral artery stenosis (&gt; 50%) documented by
                  angiography or non-invasive testing

               -  Diabetes mellitus: High-risk diabetics with evidence of end-organ damage

          2. Men and women aged â‰¥ 65 years with no history of CVD, and with at least 1 CV risk
             factor (primary prevention):

               -  History of dyslipidemia, defined as LDL cholesterol &gt; 3.5 mmol/L (135 mg/dL) or
                  HDL&lt; 1.3 mmol/L (50 mg/dL) in women or &lt; 1.0 mmol/L (39 mg/dL) in men or total
                  cholesterol/HDL ratio &gt; 5

               -  History of current or recent smoking (regular tobacco use within 5 years)

               -  Abdominal adiposity defined as waist/hip ratio â‰¥ 0.90 in women and â‰¥ 0.95 in men

               -  History of dysglycemia defined as impaired fasting glucose (IFG - fasting plasma
                  glucose 5.6 to 6.9 mmol/L [101 to 124 mg/dL]), or impaired glucose tolerance (IGT
                  - fasting plasma glucose &lt; 7 mmol/L [126 mg/dL] but 2 hour glucose 7.8 to 11.0
                  mmol/L [140 to 198 mg/dL]) or type 2 diabetes

               -  Renal dysfunction: eGFR&lt; 60 ml/min/1.73m2 but &gt; 30 ml/min/1.73m2 (MDRD formula)
                  and/or microalbuminurea/macroalbuminurea

               -  Clinical evidence of left ventricular hypertrophy

          3. Men and women aged â‰¥ 70 years if they do not have any of the above (primary
             prevention)

        Exclusion Criteria:

          1. Current treatment with aliskiren, an ACE-inhibitor, an ARB or an aldosterone
             antagonist and unable to discontinue this therapy in those without clinical vascular
             disease. Individuals with CVD or type 2 diabetes and/or renal dysfunction may receive
             an ACE-inhibitor or an ARB, but not both, contraindications to Aliskiren, Amlodipine
             or Hydrochlorothiazide.

          2. Use of both thiazide diuretic and amlodipine or another calcium channel blocker.
             Patients on only one of these two classes of drugs are eligible

          3. Uncontrolled hypertension (systolic blood pressure â‰¥ 160 mmHg and/or diastolic blood
             pressure â‰¥ 100 mmHg)

          4. Symptomatic heart failure, requiring the use of loop diuretics

          5. Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic
             or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic
             valve). Constrictive pericarditis. Complex congenital heart disease.

          6. Acute stroke &lt; 3 months or TIA â‰¤ 7 days before informed consent, acute coronary
             syndrome &lt; 1 months before informed consent

          7. Planned cardiac surgery or angioplasty &lt; 3 months after informed consent or having had
             the procedure &lt; 3 months before informed consent

          8. Severe renal impairment eGFR â‰¤ 30 ml/min/1.73m2 (MDRD formula); known renal artery
             stenosis ; serum potassium â‰¥ 5.3 mmol/L

          9. Chronic liver disease (i.e. cirrhosis, esophageal varices, portocaval shunt or
             persistent hepatitis) or abnormal liver function, i.e., alanine transaminase (ALT) or
             AST &gt; 3x upper limit of normal (ULN)

         10. Concurrent treatment with cyclosporine or quinidine; chronic use of non-steroidal
             anti-inflammatory drug (NSAIDs) or cyclooxygenase-2 (COX 2) inhibitors in patients
             with eGFR &lt; 60 ml/min/1.73m2 (MDRD formula)

         11. History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years regardless of whether
             there is evidence of local recurrence or metastases

         12. Other serious condition(s) likely to interfere with study participation or with the
             ability to complete the study. Significant psychiatric illness, senility, dementia,
             alcohol or substance abuse, which could impair the ability to provide informed consent
             and to adhere to the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pocatello</city>
        <state>Idaho</state>
        <zip>83209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63125-4181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westfiled</city>
        <state>New York</state>
        <zip>14787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Autonoma de Bs As</city>
        <state>Buenos Aires</state>
        <zip>C1119ACN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coronel Suarez</city>
        <state>Buenos Aires</state>
        <zip>B7540GHD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jenin</city>
        <state>Buenos Aires</state>
        <zip>6000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merlo</city>
        <state>Buenos Aires</state>
        <zip>1722</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878GEG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Nicolas</city>
        <state>Buenos Aires</state>
        <zip>2900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cipolletti</city>
        <state>Rio Negro</state>
        <zip>8324</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucuman</city>
        <state>San Miguel de Tucuman</state>
        <zip>T4000ICL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000AGE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Venado Tuerto</city>
        <state>Santa Fe</state>
        <zip>2600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>2800</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>8000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AWC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000AAW</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salta</city>
        <zip>A4406CLA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uberaba</city>
        <state>MG</state>
        <zip>38010-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campina Grande do Sul</city>
        <state>PR</state>
        <zip>83430-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90880-480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13060-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marilia</city>
        <state>SP</state>
        <zip>17515-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15150-210</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <state>SP</state>
        <zip>04023-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Votuporanga</city>
        <state>SP</state>
        <zip>15500-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5A 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H0R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6Z 4N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L6B 0P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Missisauga</city>
        <state>Ontario</state>
        <zip>L4Y 1A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 8C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <zip>L2G 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M2N 7J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2A 3Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2B 7K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Catherines</city>
        <state>Ontario</state>
        <zip>L2T 3Y4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C5T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4K 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>LÃ©vis</city>
        <state>Quebec</state>
        <zip>G6V 4Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sainte Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.Gorges de Beauce</city>
        <state>Quebec</state>
        <zip>G5Y 4TB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terrebonne</city>
        <state>Quebec</state>
        <zip>J6V 2H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7H 5M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1L 3L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Temuco</city>
        <state>Cautin</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vista Del Mar</city>
        <state>I Region</state>
        <zip>2570017</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Temuca</city>
        <state>TX</state>
        <zip>4790869</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osorno</city>
        <zip>5290000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cartagena</city>
        <state>Bolivar</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manizoles</city>
        <state>Caldas</state>
        <zip>1700</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pereira</city>
        <state>Risaralda</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Floridablanca</city>
        <state>Santander</state>
        <zip>57-7</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>BogotÃ¡</city>
        <zip>00000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cartegena</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Espinal</city>
        <zip>11001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monteria</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasto</city>
        <zip>745</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beroun</city>
        <zip>266 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brandys nad Labem</city>
        <zip>250 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 4</city>
        <zip>146 24</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 6</city>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 9</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Usti nad Orlici</city>
        <zip>562 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60594</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melsungen</city>
        <zip>34212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nuernberg</city>
        <zip>90471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Witten</city>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyongyos</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komarom</city>
        <zip>2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sopron</city>
        <zip>9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adoni</city>
        <state>Andhra Pradesh</state>
        <zip>518301</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adoni</city>
        <state>Andhra Pradesh</state>
        <zip>518302</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <zip>590001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bengaluru</city>
        <state>Karnataka</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>44017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wardha</city>
        <state>Maharashtra</state>
        <zip>442102</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jalandhar</city>
        <state>Punjab</state>
        <zip>144008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141421</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bikaner</city>
        <state>Rajasthan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tiruvannamalai</city>
        <state>Tamil Nadu</state>
        <zip>606603</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trichy</city>
        <state>Tamil Nadu</state>
        <zip>620018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <zip>600086</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500 063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400064</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <zip>440033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trichy</city>
        <zip>620 018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gorey</city>
        <state>Co. Wexford</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ballinsloe</city>
        <state>Galway</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Givatayim</city>
        <zip>53583</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>34616</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alor Setar</city>
        <state>Kedah</state>
        <zip>05460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kota Bahru</city>
        <state>Kelantan</state>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kota Bharu</city>
        <state>Kelantan</state>
        <zip>15586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuantan</city>
        <state>Pahang</state>
        <zip>25100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor</state>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <zip>4811SW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5611NJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>NL-9711 SG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiderdorp</city>
        <zip>2352 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3001 HG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Velp</city>
        <zip>6883ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zoetermeer</city>
        <zip>2722 EP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dasmarinas</city>
        <state>Cavite</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Laoag City</city>
        <state>Ilocos Norte</state>
        <zip>2900</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <zip>1109</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Binan City</city>
        <zip>4024</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasig City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paarl</city>
        <state>Western Province</state>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9317</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ferrol</city>
        <state>Galicia</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puerto de Sagunto</city>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dalby</city>
        <zip>247 52</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goteborg</city>
        <zip>412 55</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>GÃ¶teborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>MalmÃ¶</city>
        <zip>21152</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>RÃ¤ttvik</city>
        <zip>795 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>111 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2010</study_first_posted>
  <results_first_submitted>December 18, 2013</results_first_submitted>
  <results_first_submitted_qc>February 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2014</results_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aliskiren</keyword>
  <keyword>Elderly</keyword>
  <keyword>Major Cardiovascular Events</keyword>
  <keyword>Effect of aliskiren-based regimen on major CV events (composite of CV death, non-fatal MI, non-fatal stroke and significant heart failure) in the elderly</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren + Hydrochlorothiazide (HCTZ)</title>
          <description>In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.
In double blind period, all patients who successfully completed run-in with HCTZ plus aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily.</description>
        </group>
        <group group_id="P2">
          <title>Aliskiren + Placebo for HCTZ</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received Aliskiren 300 mg + placebo for HCTZ 25 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Aliskiren + Amlodipine</title>
          <description>In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.
In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period.</description>
        </group>
        <group group_id="P4">
          <title>Aliskiren + Placebo for Amlodipine</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received Aliskiren 300 mg + placebo for Amlodipine 5 mg</description>
        </group>
        <group group_id="P5">
          <title>HCTZ + Placebo for Aliskiren</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily</description>
        </group>
        <group group_id="P6">
          <title>Placebo for Aliskiren + Placebo for HCTZ</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily</description>
        </group>
        <group group_id="P7">
          <title>Amlodipine + Placebo for Aliskiren</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily</description>
        </group>
        <group group_id="P8">
          <title>Placebo for Aliskiren + Placebo for Amlodipine</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Run-in Open Label Period (4-5 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1335"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1001"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="980"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="779"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="355"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="222"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Double Blind Randomized Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="232"/>
                <participants group_id="P3" count="189"/>
                <participants group_id="P4" count="195"/>
                <participants group_id="P5" count="251"/>
                <participants group_id="P6" count="253"/>
                <participants group_id="P7" count="196"/>
                <participants group_id="P8" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="229"/>
                <participants group_id="P3" count="188"/>
                <participants group_id="P4" count="191"/>
                <participants group_id="P5" count="247"/>
                <participants group_id="P6" count="245"/>
                <participants group_id="P7" count="190"/>
                <participants group_id="P8" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew informed consent/ refused visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis Set (FAS): All randomized patients, regardless of receiving study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren + Hydrochlorothiazide (HCTZ)</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily.</description>
        </group>
        <group group_id="B2">
          <title>Aliskiren + Placebo for HCTZ</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received Aliskiren 300 mg + placebo for HCTZ 25 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Aliskiren + Amlodipine</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period.</description>
        </group>
        <group group_id="B4">
          <title>Aliskiren + Placebo for Amlodipine</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received Aliskiren 300 mg + placebo for Amlodipine 5 mg</description>
        </group>
        <group group_id="B5">
          <title>HCTZ + Placebo for Aliskiren</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily</description>
        </group>
        <group group_id="B6">
          <title>Placebo for Aliskiren + Placebo for HCTZ</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily</description>
        </group>
        <group group_id="B7">
          <title>Amlodipine + Placebo for Aliskiren</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were run-in stratum randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily</description>
        </group>
        <group group_id="B8">
          <title>Placebo for Aliskiren + Placebo for Amlodipine</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="244"/>
            <count group_id="B2" value="232"/>
            <count group_id="B3" value="189"/>
            <count group_id="B4" value="195"/>
            <count group_id="B5" value="251"/>
            <count group_id="B6" value="253"/>
            <count group_id="B7" value="196"/>
            <count group_id="B8" value="199"/>
            <count group_id="B9" value="1759"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;=65 to &lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="180"/>
                    <measurement group_id="B6" value="189"/>
                    <measurement group_id="B7" value="135"/>
                    <measurement group_id="B8" value="134"/>
                    <measurement group_id="B9" value="1229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="64"/>
                    <measurement group_id="B7" value="61"/>
                    <measurement group_id="B8" value="65"/>
                    <measurement group_id="B9" value="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="122"/>
                    <measurement group_id="B6" value="108"/>
                    <measurement group_id="B7" value="87"/>
                    <measurement group_id="B8" value="88"/>
                    <measurement group_id="B9" value="813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="129"/>
                    <measurement group_id="B6" value="145"/>
                    <measurement group_id="B7" value="109"/>
                    <measurement group_id="B8" value="111"/>
                    <measurement group_id="B9" value="946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen</title>
        <description>The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure</description>
        <time_frame>End of study (209 days (median))</time_frame>
        <population>Full Analysis set. 1759 patients were randomized as against the originally planned 11,000. A total of 25 primary CV composite endpoints had accrued during median follow-up of 209 days versus planned 2000 primary endpoints during planned follow-up of average 5 years. These low numbers significantly limit interpretation of the results.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that included Aliskiren such as Aliskiren + hydrochlorothiazide (HCTZ), Aliskiren + placebo for HCTZ, Aliskiren + Amlodipine, Aliskiren + placebo for Amlodipine.</description>
          </group>
          <group group_id="O2">
            <title>Non-Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that did not include Aliskiren such as HCTZ + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for HCTZ, Amlodipine + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for Amlodipine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen</title>
          <description>The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure</description>
          <population>Full Analysis set. 1759 patients were randomized as against the originally planned 11,000. A total of 25 primary CV composite endpoints had accrued during median follow-up of 209 days versus planned 2000 primary endpoints during planned follow-up of average 5 years. These low numbers significantly limit interpretation of the results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="860"/>
                <count group_id="O2" value="899"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Study in Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part I)</title>
        <description>Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in last month. Each questionâ€™s score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part I of SAGE included 4 dimensions:
Community Cognition (maximum of scores of questions 1 to 6);
Instrumental Activities of daily Living (IADL) (maximum of scores of questions 7 to 10);
Mobility (maximum of scores of questions 11 and 12);.
Basic Activities of daily Living (ADL) (maximum of scores of questions 13 to 15) Each dimensionâ€™s total score ranged from 0 to 3. 0=best, 3=worst A negative change in value from baseline means improvement in the ability to perform everyday activities.</description>
        <time_frame>Baseline, End of study (209 days [median])</time_frame>
        <population>Full Analysis Set: Due to the sparse post-baseline data following early termination of the study, this analysis was not performed as planned in protocol.Hence, no meaningful conclusion could be drawn. Patients who completed both baseline and post-baseline SAGE questionnaires (Part II) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that included Aliskiren such as Aliskiren + Hydrochlorothiazide (HCTZ), Aliskiren + placebo for HCTZ, Aliskiren + Amlodipine, Aliskiren + placebo for Amlodipine.</description>
          </group>
          <group group_id="O2">
            <title>Non-Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that did not include Aliskiren such as HCTZ + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for HCTZ, Amlodipine + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for Amlodipine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Study in Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part I)</title>
          <description>Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in last month. Each questionâ€™s score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part I of SAGE included 4 dimensions:
Community Cognition (maximum of scores of questions 1 to 6);
Instrumental Activities of daily Living (IADL) (maximum of scores of questions 7 to 10);
Mobility (maximum of scores of questions 11 and 12);.
Basic Activities of daily Living (ADL) (maximum of scores of questions 13 to 15) Each dimensionâ€™s total score ranged from 0 to 3. 0=best, 3=worst A negative change in value from baseline means improvement in the ability to perform everyday activities.</description>
          <population>Full Analysis Set: Due to the sparse post-baseline data following early termination of the study, this analysis was not performed as planned in protocol.Hence, no meaningful conclusion could be drawn. Patients who completed both baseline and post-baseline SAGE questionnaires (Part II) were included in this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="592"/>
                <count group_id="O2" value="618"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Community Cognition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.768"/>
                    <measurement group_id="O2" value="-0.05" spread="0.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Instrumental Activities of daily Living (IADL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.562"/>
                    <measurement group_id="O2" value="-0.04" spread="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.791"/>
                    <measurement group_id="O2" value="0.00" spread="0.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.525"/>
                    <measurement group_id="O2" value="-0.08" spread="0.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
        <description>Mean sitting systolic blood pressure (msSBP) is the average of 2 sitting SBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.</description>
        <time_frame>Baseline (BL), 6 week, 6 month and 12 month</time_frame>
        <population>Full analysis Set : All randomized patients, regardless of receiving study medication. n=number of patients with non-missing assessments at baseline and each post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that included Aliskiren such as Aliskiren + Hydrochlorothiazide (HCTZ), Aliskiren + placebo for HCTZ, Aliskiren + Amlodipine, Aliskiren + placebo for Amlodipine.</description>
          </group>
          <group group_id="O2">
            <title>Non-Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that did not include Aliskiren such as HCTZ + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for HCTZ, Amlodipine + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for Amlodipine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
          <description>Mean sitting systolic blood pressure (msSBP) is the average of 2 sitting SBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.</description>
          <population>Full analysis Set : All randomized patients, regardless of receiving study medication. n=number of patients with non-missing assessments at baseline and each post-baseline visit.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="860"/>
                <count group_id="O2" value="899"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from Baseline to 6 week (n=821,867)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="0.50"/>
                    <measurement group_id="O2" value="-8.02" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to 6 month (n=730,775)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="0.52"/>
                    <measurement group_id="O2" value="-6.8" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to 12 month (n=397,399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="0.68"/>
                    <measurement group_id="O2" value="-5.8" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite Cardiovascular Endpoints in Aliskiren+Amlodipine/HCTZ Group Versus All Placebo Group</title>
        <description>The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure</description>
        <time_frame>End of study (209 days (median))</time_frame>
        <population>Full Analysis set. 1759 patients were randomized as against the originally planned 11,000. A total of 25 primary CV composite endpoints had accrued during median follow-up of 209 days versus planned 2000 primary endpoints during planned follow-up of average 5 years. These low numbers significantly limit interpretation of the results.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren+Amlodipine/HCTZ Group</title>
            <description>This reporting group includes all the patients who has received Aliskiren plus an additional BP lowering drug (Amlodipine or Hydrochlorothiazide). This reporting group includes patients from arms such as Aliskiren + Hydrochlorothiazide (HCTZ) and Aliskiren + Amlodipine.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>This reporting group includes all the patients who has received placebo of aliskiren plus placebo of an additional BP lowering drug (amlodipine or hydrochlorothiazide). This reporting group includes patients from arms such as Placebo for Aliskiren + Placebo for HCTZ and Placebo for aliskiren + Placebo for Amlodipine .</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Cardiovascular Endpoints in Aliskiren+Amlodipine/HCTZ Group Versus All Placebo Group</title>
          <description>The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure</description>
          <population>Full Analysis set. 1759 patients were randomized as against the originally planned 11,000. A total of 25 primary CV composite endpoints had accrued during median follow-up of 209 days versus planned 2000 primary endpoints during planned follow-up of average 5 years. These low numbers significantly limit interpretation of the results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part II)</title>
        <description>Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE was comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in the last month. Each questionâ€™s score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)).
Part II of SAGE included 2 dimensions:
&quot;Normal&quot; if the scores of all SAGE questions is 0 (i.e., No difficulty)
&quot;Mobility Only&quot; if scores of both SAGE questions 11 and 12 are 0</description>
        <time_frame>End of study (209 days [median])</time_frame>
        <population>Full Analysis Set. Number of patients with all SAGE questions non-missing for the specific visit are included in this population. Due to the sparse post-baseline data following early termination of the study, this analysis was not performed as planned in protocol.Hence, no meaningful conclusion could be drawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that included Aliskiren such as Aliskiren + hydrochlorothiazide (HCTZ), Aliskiren + placebo for HCTZ, Aliskiren + Amlodipine, Aliskiren + placebo for Amlodipine.</description>
          </group>
          <group group_id="O2">
            <title>Non-Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that did not include Aliskiren such as HCTZ + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for HCTZ, Amlodipine + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for Amlodipine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part II)</title>
          <description>Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE was comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in the last month. Each questionâ€™s score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)).
Part II of SAGE included 2 dimensions:
&quot;Normal&quot; if the scores of all SAGE questions is 0 (i.e., No difficulty)
&quot;Mobility Only&quot; if scores of both SAGE questions 11 and 12 are 0</description>
          <population>Full Analysis Set. Number of patients with all SAGE questions non-missing for the specific visit are included in this population. Due to the sparse post-baseline data following early termination of the study, this analysis was not performed as planned in protocol.Hence, no meaningful conclusion could be drawn.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="608"/>
                <count group_id="O2" value="641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2"/>
                    <measurement group_id="O2" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility Only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8"/>
                    <measurement group_id="O2" value="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Renal Dysfunction in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen</title>
        <description>The renal dysfunction (composite endpoint) was defined as the first occurrence of either of the following:
End-stage renal disease [ESRD] requiring dialysis or transplantation
Doubling of serum creatinine and reaching an eGFR &lt; 45 ml/min/1.73 m^2.</description>
        <time_frame>End of study (209 days (median))</time_frame>
        <population>Full Analysis set. 1759 patients were randomized as against the originally planned 11,000. The duration of study follow-up was 209 days (median) as against the planned follow-up of average 5 years. These low numbers significantly limit interpretation of the results.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that included Aliskiren such as Aliskiren + Hydrochlorothiazide (HCTZ), Aliskiren + placebo for HCTZ, Aliskiren + Amlodipine, Aliskiren + placebo for Amlodipine.</description>
          </group>
          <group group_id="O2">
            <title>Non-Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that did not include Aliskiren such as HCTZ + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for HCTZ, Amlodipine + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for Amlodipine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Renal Dysfunction in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen</title>
          <description>The renal dysfunction (composite endpoint) was defined as the first occurrence of either of the following:
End-stage renal disease [ESRD] requiring dialysis or transplantation
Doubling of serum creatinine and reaching an eGFR &lt; 45 ml/min/1.73 m^2.</description>
          <population>Full Analysis set. 1759 patients were randomized as against the originally planned 11,000. The duration of study follow-up was 209 days (median) as against the planned follow-up of average 5 years. These low numbers significantly limit interpretation of the results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="860"/>
                <count group_id="O2" value="899"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ESRD requiring dialysis or transplantation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Doubling of creatinine &amp; eGFR&lt;45 ml/min/1.73 m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>Mean sitting diastolic blood pressure (msDBP) is the average of 2 sitting DBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.</description>
        <time_frame>Baseline (BL), 6 week, 6 month and 12 month</time_frame>
        <population>Full analysis Set : All randomized patients, regardless of receiving study medication. n=number of patients with non-missing assessments at baseline and each post-baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that included Aliskiren such as Aliskiren + Hydrochlorothiazide (HCTZ), Aliskiren + placebo for HCTZ, Aliskiren + Amlodipine, Aliskiren + placebo for Amlodipine.</description>
          </group>
          <group group_id="O2">
            <title>Non-Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that did not include Aliskiren such as HCTZ + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for HCTZ, Amlodipine + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for Amlodipine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>Mean sitting diastolic blood pressure (msDBP) is the average of 2 sitting DBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis.</description>
          <population>Full analysis Set : All randomized patients, regardless of receiving study medication. n=number of patients with non-missing assessments at baseline and each post-baseline visit.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="860"/>
                <count group_id="O2" value="899"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>change from Baseline to 6 week (n=821,867)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="0.31"/>
                    <measurement group_id="O2" value="-3.6" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to 6 month (n=730,775)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="0.33"/>
                    <measurement group_id="O2" value="-3.5" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change from baseline to 12 month (n=397,399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="0.43"/>
                    <measurement group_id="O2" value="-3.9" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen</title>
        <description>The total mortality endpoint was defined as time to death from any cause. Total mortality analysis used the date of last follow-up including the washout period as the censoring date.</description>
        <time_frame>End of study (209 days (median))</time_frame>
        <population>Full Analysis set. 1759 patients were randomized as against the originally planned 11,000. The duration of study follow-up was 209 days (median) as against the planned follow-up of average 5 years. These low numbers significantly limit interpretation of the results.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that included Aliskiren such as Aliskiren + Hydrochlorothiazide (HCTZ), Aliskiren + placebo for HCTZ, Aliskiren + Amlodipine, Aliskiren + placebo for Amlodipine.</description>
          </group>
          <group group_id="O2">
            <title>Non-Aliskiren Based Regimen</title>
            <description>This regimen includes all the patients who were randomized to the treatment arms that did not include Aliskiren such as HCTZ + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for HCTZ, Amlodipine + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for Amlodipine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen</title>
          <description>The total mortality endpoint was defined as time to death from any cause. Total mortality analysis used the date of last follow-up including the washout period as the censoring date.</description>
          <population>Full Analysis set. 1759 patients were randomized as against the originally planned 11,000. The duration of study follow-up was 209 days (median) as against the planned follow-up of average 5 years. These low numbers significantly limit interpretation of the results.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="860"/>
                <count group_id="O2" value="899"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Set (SAF): The safety set consists of all randomized patients who took at least one dose of study medication. Patients were analyzed according to treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Run-in Period: Aliskiren + Hydrochlorothiazide (HCTZ)</title>
          <description>In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.
Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily.</description>
        </group>
        <group group_id="E2">
          <title>Run-in Period: Aliskiren + Amlodipine</title>
          <description>In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.
Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period.</description>
        </group>
        <group group_id="E3">
          <title>Double Blind Period: Aliskiren + Hydrochlorothiazide (HCTZ)</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily.</description>
        </group>
        <group group_id="E4">
          <title>Double Blind Period: Aliskiren + Placebo for HCTZ</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received Aliskiren 300 mg + placebo for HCTZ 25 mg once daily</description>
        </group>
        <group group_id="E5">
          <title>Double Blind Period: Aliskiren + Amlodipine</title>
          <description>In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period.</description>
        </group>
        <group group_id="E6">
          <title>Double Blind Period: Aliskiren + Placebo for Amlodipine</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received Aliskiren 300 mg + placebo for Amlodipine 5 mg</description>
        </group>
        <group group_id="E7">
          <title>Double Blind Period: HCTZ + Placebo for Aliskiren</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily</description>
        </group>
        <group group_id="E8">
          <title>Double Blind Period: Placebo for Aliskiren + Placebo for HCTZ</title>
          <description>In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily</description>
        </group>
        <group group_id="E9">
          <title>Double Blind Period: Amlodipine + Placebo for Aliskiren</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily</description>
        </group>
        <group group_id="E10">
          <title>Double Blind Period: Placebo for Aliskiren + Placebo for Amlod</title>
          <description>In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hypoperfusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1335"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1001"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="251"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to early termination, 1759 patients were randomized as against 11,000. Only 25 primary endpoints had accrued during median follow-up of 209 days as against planned 2000 in 5 years. These low numbers significantly limit interpretation of results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

